United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read General business news Volatus Aerospace restates Q2 2025 results after accounting adjustment with no revenue impact Volatus Aerospace restated its Q2 2025 results after a non-cash accounting adjustment. Find out how the move affects investor confidence and long-term growth. bySoujanya RaviNovember 3, 2025